GSK (GSK.US) ADC therapy positive phase 3 clinical results, extending the lives of patients with refractory cancer.

GSK (GSK.US) announced today that its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) has achieved positive results in the planned interim analysis of the phase 3 clinical trial DREAMM-7. The trial evaluated the efficacy of Blenrep in combination with bortezomib and dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma. The trial met the key secondary endpoint of overall survival (OS), showing that Blenrep in combination with BorDex significantly reduced the risk of death compared to standard treatment. The results of the interim analysis, including safety data, will be presented at the upcoming 66th American Society of Hematology (ASH) annual meeting. Blenrep is a targeted antibody-drug conjugate that targets B-cell maturation antigen (BCMA), consisting of a humanized anti-BCMA monoclonal antibody linked with the cytotoxic payload auristatin F through a non-cleavable linker.